Incyte (INCY) Stock Concentration Calculator
Calculator · free · no signup · INCYQuantify Incyte concentration risk. Drawdown impact at 30 / 50 / 70%, with the tax-aware trade-off between selling down and hedging.
AlphaLatitude Inc. · Free ToolsOur tools respect your browsing privacy. Independently verified:
Your inputs
Adjust — results update instantly.Position & portfolio
Tax
Most fee-only advisors target ≤10% in any single name. You're at 67%.
Estimates only. Not financial advice.
Most sensitive to: Expected market return (±10% on this input swings best-plan wealth by ±$190,508).
Cost of fully de-concentrating
All three plans sell to 0% (no hedge).Sensitivity. If your expected position return drops below 19.6%/yr, lump-sum (sell everything today) beats every spread plan above.
Have multiple RSU vest lots? The RSU Lot Order Calculator picks which lots to sell first, and on which dates, to divest at the lowest computed tax.
Build your own plan
Toggle below — chart updates live. Sell buttons show the slice.Tech / Software single names hit a 50%+ peak-to-trough drawdown in roughly 1 of every 5 rolling 3-year windows over 2014–2024. Even mega-caps aren’t exempt.
Tax brackets: 2026 · Estimates only — not financial advice.
Estate note. Heirs receive a stepped-up basis at death (§1014), eliminating built-in gain on inherited shares. Older holders who plan to bequeath rather than sell may rationally never de-concentrate.
You sized one position's risk. The beta integrates hedging, sell-down, and tax timing into one optimized plan.
Request beta access →Related calculators: Protect Your Stock Calculator · RSU Lot Order Calculator · Equity Funding Plan Calculator
About Incyte
Incyte (INCY) is a public Pharma/Biotech company, incorporated in Delaware and headquartered in Wilmington, DE.
Last close: $115.3 per share (as of 2026-10-03).
Equity grants at Incyte typically include restricted stock units (RSUs).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Source: Wikipedia (CC BY-SA 4.0)
The company built itself around Jakafi, a JAK inhibitor approved in 2011 for myelofibrosis and later for other conditions, which supplies most of its revenue. That concentration is the central fact of the investment case: the compound's patent life sets a deadline the pipeline has to beat. Research has extended into dermatology and additional oncology indications, some through partnerships that share development cost. Unlike larger peers, the company has neither the scale nor the cash to acquire its way out of a gap. Headquarters are in Wilmington, Delaware.
Sources: sec.gov · en.wikipedia.org
Equity comp at Incyte
- For most employees, unvested RSUs and options continue on their normal schedule through a merger or acquisition if the new owner assumes or replaces the awards, and only accelerate (vest early) if the holder is also let go without cause afterward, the standard double-trigger structure. But if an acquirer does not assume or replace the awards, they vest in full immediately at the deal close, a single-trigger fallback common in biotech merger agreements. Executive Vice Presidents and above have added severance terms: if terminated without cause, or if they resign for a qualifying reason, within 24 months after a change in control, they receive 2x salary plus target bonus and full acceleration of unvested equity. Named executives also receive Performance Shares that cliff vest (all at once, not gradually) on the third anniversary of grant, paying out 0 to 200 percent of target based on Incyte's total shareholder return relative to the Nasdaq Biotechnology Index peer group.
- RSUs use double-trigger vesting. Two things must both happen before the shares are yours: (1) the normal time-based vesting completes, and (2) the company has a liquidity event (an IPO or an acquisition). Until both happen, you do not yet own the shares and you do not owe tax on them.
Sources: sec.gov · sec.gov · sec.gov
Researched 2026-08-23.
OptionsAhoy is an independent tool and is not affiliated with, endorsed by, or sponsored by Incyte.
If a meaningful share of your net worth sits in INCY, concentration risk is the question. This calculator quantifies drawdown impact at 30 / 50 / 70%, and the trade-off between selling down (tax cost now) versus hedging (option premium drag), auto-filled with INCY's option-implied volatility.
Example: 5,000 INCY shares at $115.3 is a $576,500 position. A 30% drawdown costs $172,950; a 50% drawdown costs $288,250; a 70% drawdown costs $403,550. The calculator quantifies the trade-off between selling down (immediate capital-gains tax) and hedging (option premium drag) using INCY's option-implied volatility and your cost basis.
All Incyte tools → · Use the generic Stock Concentration Calculator for any company. Diversifying multiple RSU lots? See the lot-by-lot sell order →
Incyte equity questions
- How much INCY stock is too much?
- There is no single threshold, but the larger the share of your net worth in one stock, the more a single bad year can set back your plans. The calculator above quantifies the drawdown impact at 30, 50, and 70 percent for your INCY position and weighs selling down (which triggers capital-gains tax now) against hedging (which costs option premium).
- Does Incyte grant ISOs, NSOs, or RSUs?
- Equity compensation at Incyte typically takes the form of restricted stock units (RSUs). Restricted stock units are taxed as ordinary income when they vest.
- Do Incyte RSUs use double-trigger vesting?
- Yes. Incyte restricted stock units (RSUs) vest only when two things both happen: the time-based schedule completes, and the company has a liquidity event such as an initial public offering (IPO) or an acquisition. Until both occur you do not own the shares and owe no tax on them.
Find another companyPharma/Biotech peers
One piece of the puzzle.
OptionsAhoy plans your Incyte equity alongside hedging, vesting, and de-concentration, across bullish, neutral, and bearish market scenarios. Free during beta.